Blending both genetic test status AND personal cancer family history, Myriad myRisk hereditary cancer panel represents the next generation of hereditary cancer risk testing. Myriad myRisk identifies elevated risk for 8 important cancers by analyzing multiple, clinically significant genes. In addition, myRisk’s assessment of the BRCA1 and BRCA2 genes can help inform treatment decisions related to PARP inhibitor therapy.1
Inform Treatment Decisions
- Knowing BRCA1 and BRCA2 status may inform treatment decisions related to PARP inhibitors
- In the OlympiAD trial of patients with HER2-negative metastatic breast cancer and a germline BRCA mutation, the risk of progression or death was 42% lower with olaparib monotherapy than with standard therapy1
Manage Future Cancer Risk
- Myriad myRisk simplifies the test selection process by providing you the most comprehensive hereditary cancer panel test with clinically significant results. Be confident you are testing for the primary clinically significant genes associated with your patients’ risk.
- First-degree relatives of these patients are at a 50% risk for carrying the mutation.
- Those relatives who are positive may benefit from increased surveillance and/or preventive measures.
In the OlympiAD Trial, in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation, olaparib monotherapy provided a significant benefit over standard therapy by reducing the risk of disease progression or death by 42%.
This practice-changing evidence highlights the need for the identification and testing of all appropriate patients for hereditary breast cancer to identify the BRCA mutation carriers in order to inform therapeutic decisions. Additionally, studies such as TNT and GeparSixto highlight the clinical utility of knowing BRCA1/2 status in patients when making treatment decisions related to DNA-damaging chemotherapy.
Explore these publications to learn more about how BRCA1/2 can impact treatment decisions related to PARP inhibitor therapy and DNA-damaging chemotherapy.
Myriad is the unquestioned industry leader in variant classification and reclassification. myVision® is the most advanced program in the industry overseeing the classification and reclassification of uncertain variants and is part of Myriad’s commitment to patients and their families that lasts a lifetime.
MYRIAD HAS CONDUCTED OVER
TESTS FOR HEREDITARY CANCER
* BRACAnalysis CDx has been approved by the FDA for patients with breast and ovarian cancer who are or may become eligible for treatment with the PARP inhibitor Lynparza® (olaparib). BRACAnalysis CDx can also identify patients with ovarian cancer who may experience enhanced progression-free survival (PFS) from Zejula® (niraparib) maintenance therapy. myRisk, myChoice HRD and BRACAnalysis have not been reviewed or approved by the FDA.1,2
- Robson et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med (2017). 377:523-533